Tiziana Life Sciences Begins Dosing Last Patient In Its Phase 2 Clinical Trial Evaluating Intranasal Foralumab In Patients With Early/Mild Alzheimer’s Disease; Topline Data Anticipated In Q1 2027

Benzinga

2026.10.16 11:05 (GMT+0)

Benzingaで開く